New hope for rare leukemia: phase 3 trial of IMM01 combo launches
NCT ID NCT06647862
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding IMM01 (Timdarpacept) to standard azacitidine improves outcomes for people newly diagnosed with chronic myelomonocytic leukemia (CMML). About 170 participants will receive either the combination or a placebo plus azacitidine. The main goals are complete remission and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IMM01 (Timdarpacept) combined with azacitidine
- What this could lead to
- If successful, this combination could become a new standard treatment for chronic myelomonocytic leukemia, improving remission rates and overall survival.
- What could go wrong
- This is an early Phase 3 trial with 170 participants, so results may not confirm benefit. The drug combination may cause side effects like infusion reactions or bone marrow suppression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, China
-
Affiliated Hospital of Hebei University
NOT_YET_RECRUITINGShijiazhuang, Hebei, China
-
Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, China
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, China
-
Changzhou First People's Hospital
RECRUITINGChangzhou, Jiangsu, China
-
China-Japan Friendship Hospita
RECRUITINGBeijing, Beijing Municipality, China
-
First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
-
First Hospital of Lanzhou University
NOT_YET_RECRUITINGLanzhou, Gansu, China
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangzhou, China
-
Harbin First Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
-
Henan Provincial People's Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College;
RECRUITINGTianjin, Tianjin Municipality, 300020, China
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, China
-
Jiangsu Subei People's Hospital
RECRUITINGYangzhou, Jiangsu, China
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, China
-
Ningbo First Hospital
RECRUITINGNingbo, Zhejiang, China
-
Peking University People's Hospital
NOT_YET_RECRUITINGBeijing, China
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, China
-
Shaanxi Provincial People's Hospital
RECRUITINGXi’an, Shanxi, China
-
Shengjing Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
-
Shenzhen Second People's Hospital
NOT_YET_RECRUITINGShenzhen, Guangdong, China
-
Sichuan Provincial People's Hospital
NOT_YET_RECRUITINGChengdu, Sichuan, China
-
The First Affiliated Hospital of Chongqing Medical University
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, China
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Gaungxi, China
-
The First Affiliated Hospital of Henan University of Science and Technology
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, China
-
The First Affiliated Hospital of Soochow University
NOT_YET_RECRUITINGSuzhou, Jiangsu, China
-
The First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITINGWenzhou, Zhejiang, China
-
The First Affiliated Hospital of Xinjiang Medical University
RECRUITINGÜrümqi, Xinjiang, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
-
The First Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, China
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, China
-
The Second Affiliated Hospital of Kunming Medical University
NOT_YET_RECRUITINGKunming, Yunnan, China
-
The Second Hospital of Hebei Medical University
NOT_YET_RECRUITINGShijiazhuang, Hebei, China
-
Tianjin People's Hospital
RECRUITINGTianjin, China
-
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
-
Xiangya Hospital Central South University
NOT_YET_RECRUITINGChangsha, Hunan, China
-
Xiangyang Central Hospital
RECRUITINGXiangyang, Hubei, China
-
Yibin Second People's Hospital
RECRUITINGYibin, Sichuan, China
-
Zhongda Hospital affiliated to Southeast University
RECRUITINGNanjing, Jiangsu, China
-
Zhongnan Hospital Affiliated to Wuhan University
NOT_YET_RECRUITINGWuhan, Hubei, China
-
Zhujiang Hospital of Southern Medical University
NOT_YET_RECRUITINGZhujiang, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a Two-Drug combo tame a rare blood cancer?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a new pill take on Hard-to-Treat leukemia?
- Targeted drug aims to stop blood cancer return after transplant
- Three-Drug cocktail aims to tame transplant complications in blood cancer patients